Virtual Bronchoscopy Transbronchial Needle Aspiration(TBNA): a Proof of Concept Study

This study has been terminated.
Sponsor:
Collaborator:
Philips Healthcare
Information provided by:
VU University Medical Center
ClinicalTrials.gov Identifier:
NCT01077492
First received: February 26, 2010
Last updated: November 1, 2012
Last verified: February 2010
  Purpose

The purpose of this study is to determine wether CT-PET virtual bronchoscopy guided transbronchial needle aspiration is suitable for the investigation of mediastinal lymph nodes which is needed for correct staging of lung cancer.


Condition Intervention
Lung Cancer
Other: Virtual Bronchoscopy Navigation

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: CT-PET Virtual Bronchoscopy Guided Transbronchial Needle Aspiration for Mediastinal Lymph Node Staging in Suspected Lung Cancer

Resource links provided by NLM:


Further study details as provided by VU University Medical Center:

Primary Outcome Measures:
  • Feasibility of VB in determining N2/N3 mediastinal lymph nodes [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Feasibility of virtual bronchoscopy in showing the presence or abscense of N2/N3 mediastinal lymph node (MLN) metastasis with accuracy of 0.6 in puncturing MLN > 15 mm (CT images) and accuracy of 0.8 for MLN < 15 mm in the second phase of the study.


Secondary Outcome Measures:
  • Duration of the session within the optimal time window of local anesthesia using lidocaine 1%; comparable to standard routine bronchoscopic procedure on an outpatient basis, i.e. not exceeding 30 minutes. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Enrollment: 80
Study Start Date: April 2010
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Suspected mediastianl lymph nodes
Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
Other: Virtual Bronchoscopy Navigation
Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.

Detailed Description:

Accurate staging of mediastinal lymph nodes (MLNs) in patients with lung carcinoma (LC) is paramount as the N stage largely determines treatment strategy, prognosis and outcome. Surgical staging such as mediastinoscopy is considered the gold standard. A less invasive alternative is transbronchial needle aspiration (TBNA). This technique is limited however by moderate and operator dependent accuracy. Recently less invasive strategies such as esophageal ultrasound guided fine needle aspiration (EUS-FNA) and endobronchial ultrasound guided TBNA (EBUS-TBNA) were introduced. These strategies have largely complemented TBNA and surgical staging, with high accuracy and low morbidity. Disadvantages compared to TBNA however are required specific expertise, higher equipment and maintenance costs, the need for more assisting personnel and the need for sedation. Advances in computer generated image processing based on available CT and PET images enable (quasi) real-time virtual bronchoscopy that can assist minimal invasive surgical performance including bronchoscopy. Optimizing the traditional TBNA procedure with these modern imaging techniques might be equally accurate and more cost effective.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with suspected lung cancer requiring mediastinal lymph node staging after CT-PET scan during routine work-up according to local guidelines.

Criteria

Inclusion Criteria:

  • Age > 18 years
  • Proven or suspected lung cancer, base on clinical picture and/or CT-PET findings
  • Suspected involvement of mediastinal lymph nodes on CT-PET scan
  • Written informed consent

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01077492

Locations
Netherlands
VU University Medical Center
Amsterdam, Netherlands, 1081 HV
Sponsors and Collaborators
VU University Medical Center
Philips Healthcare
Investigators
Study Chair: Sayed Hashemi, MD VU University Medical Center
Study Chair: Hans Daniels, MD VU University Medical Center
Study Chair: Emiel Comans, PhD VU University Medical Center
Study Chair: Otto Hoekstra, PhD VU University Medical Center
Study Chair: Piet Postmus, PhD VU University Medical Center
Principal Investigator: Tom Sutedja, PhD VU University Medical Center
  More Information

No publications provided

Responsible Party: T.G. Sutedja, MD, PhD, VU University Medical Center
ClinicalTrials.gov Identifier: NCT01077492     History of Changes
Other Study ID Numbers: 09/327
Study First Received: February 26, 2010
Last Updated: November 1, 2012
Health Authority: Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by VU University Medical Center:
lung cancer
mediastinal lymph nodes
TBNA
staging lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014